246250 · KOSDAQ · ₩246250 · 에스엘에스바이오
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩1,969Today: ₩1,969 – ₩1,969₩1,969
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
SLSBio(Specialty Lab Solution Bio) (에스엘에스바이오, KRX: 246250) is listed on KOSDAQ, in the Business services sector. The company was established in 2007 and provides pharmaceutical quality control testing, new drug development support services, and in vitro diagnostic devices. Its shares closed at ₩1,969 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩30B.
The company was established in 2007 and provides pharmaceutical quality control testing, new drug development support services, and in vitro diagnostic devices. Its quality control business tests finished drugs and imports for pharmaceutical clients, offering services such as dissolution testing, stability testing, and validation, and it supports domestic drugmakers seeking overseas approval. It also provides drug discovery testing for pharmaceutical companies and is developing allergy and bovine pregnancy diagnostic kits, with operations centered in South Korea.
Written by AI from the company's latest annual report.
High impactPredicted impact: High
Delisting and trading halt; repeat of earlier delisting news, but a major listing event, so kept high.
Predicted impact: Low
Testing revenue recovery and new business expansion are vague, with no figures given.
Titles in Korean until English translations are added.
Also known as: SLSBio(Specialty Lab Solution Bio) / 에스엘에스바이오 / 246250 / KRX:246250
Source: KRX statistical information